Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
The study found that in NSCLC patients with pCR, neoadjuvant ICI reduced tumor recurrence rate. This indicated that like in advanced stage NSCLC, the ICI might bring similar long-term anti-tumor effect in operable NSCLC patients.
Authors
- Zhouyang Li (ORCID: https://orcid.org/0000-0002-7721-0175)
- Yanxiong Mao (ORCID: https://orcid.org/0000-0002-7033-3383)
- Yimin Zou (ORCID: https://orcid.org/0000-0002-1092-5547)
- Fen Lan
- Zhangqun Ye (ORCID: https://orcid.org/0000-0002-7390-214X)
- Bo Fan (ORCID: https://orcid.org/0000-0001-5487-1600)
- Wen Li (ORCID: https://orcid.org/0000-0001-8808-9852)
- Fei Chen (ORCID: https://orcid.org/0000-0001-5690-5691)
Institutions
- Zhejiang Cancer Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Ningbo First Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1186/s12885-024-13142-4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00